NorthWest Biotherapeutics Inc (NWBO)

[VMLG17]

I just sent ARK Invest the following message via their website: ...your analysts should seriously be considering adding Northwest Biotherapeutics (NWBO) to the ARKG ETF. This could be a 100-bagger in five years as their dendritic cell vaccines, DCVax-L (for operable tumors) and DCVax-Direct (for inoperable tumors) become standard of care. Their 12-year clinical trial of DCVax-L for the treatment of glioblastoma brain cancer reached data lock over five months ago, and publication of the results in a scientific journal and top line data are imminent...Who knows, maybe it’ll reach Cathie Wood herself if NWBO isn’t on her radar screen already. If all of us did the same, it probably wouldn’t go unnoticed.